Report Details:
15 Companies Covered
110 Pages
Increasing Use of New Treatments for Kidney Diseases Boosts the Market Growth
The global chronic kidney disease (CKD) market is poised for consistent growth over the forecast period, reaching a valuation of USD 179.73 billion by 2035 from USD 112.49 billion in 2024, registering a CAGR of 4.41%.
The market growth is primarily driven by the increasing prevalence of chronic kidney disease, rising awareness about early diagnosis and treatment, and growing investments in advanced therapies and dialysis technologies.
Furthermore, the expanding geriatric population and rising incidences of hypertension and diabetes have significantly contributed to the surge in CKD cases worldwide.
Market Overview
Chronic kidney disease is a progressive medical condition in which the kidneys gradually lose their ability to function effectively, leading to the accumulation of waste and fluid in the body. The increasing patient pool, coupled with greater healthcare expenditure, is driving market expansion.
Additionally, the growing adoption of technologically advanced treatment devices, particularly in hemodialysis and peritoneal dialysis, is expected to further augment market performance.
The market’s steady progression is also being supported by the increased adoption of digital health tools and AI-powered diagnostic systems, which enable early disease detection and continuous patient monitoring.
The emphasis on value-based care and patient-centered management models has further improved treatment accessibility and clinical outcomes.
Segment Insights
The global chronic kidney disease market has been segmented by diagnosis, treatment, indication, end user, and region. Based on diagnosis, the market is governed by the blood test category. The simplicity of the category is generating more demand for the category.
The kidney biopsy category, on the other hand, gained traction recently, owing to the accuracy and precision of the test in detecting chronic kidney-related diseases. This fuels the demand for the category at the highest rate, among other categories.
By treatment, the market is classified into dialysis and kidney transplant. The dialysis segment holds a significant share of the market due to the high number of patients requiring long-term dialysis support.
Within dialysis, the hemodialysis sub-segment continues to lead, attributed to advancements in machine design, improved membrane efficiency, and increasing hospital-based treatment setups.
However, peritoneal dialysis is gaining attention owing to its convenience and growing preference for home-based care solutions. In terms of end users, hospitals and dialysis centers account for the largest revenue share.
Based on the indication segment, the market can be bifurcated into the high blood pressure category and the Type 1 or Type 2 diabetes category. With the rising concern for diabetic patients, the category is expected to propagate faster against the highest market share holder, the high BP category.
The availability of skilled nephrologists, better reimbursement structures, and advanced facilities make hospitals the primary choice for treatment. Meanwhile, specialty clinics and home care settings are gradually expanding due to the rise in telemedicine and portable dialysis technologies.
Regional Insights
Regionally, North America held the dominant position, accounting for around 45% of the market share, in the chronic kidney disease market, driven by strong healthcare infrastructure, early adoption of innovative therapies, and the growing burden of diabetes and hypertension.
The US contributes the majority share owing to favorable government initiatives, a robust reimbursement framework, and the presence of leading pharmaceutical companies focused on CKD therapeutics.
Europe, which secured 30% of the market share, followed closely, with countries such as Germany, the UK, and France actively investing in renal research and public awareness programs. The Asia-Pacific region, however, is expected to record the fastest growth rate during the forecast period. The region held 20% of the market space.
This growth is attributed to a rapidly aging population, increased healthcare spending, and improved access to medical facilities in countries such as China, India, and Japan. Moreover, rising government efforts to improve kidney care infrastructure and promote affordable dialysis services are expected to strengthen regional growth further.
The Rest of the World segment, including Latin America and the Middle East & Africa, accounting for 5% of the market share, is also showing promising development, mainly due to expanding healthcare systems, increasing awareness about kidney health, and gradual improvements in medical insurance coverage.
Key Players
Prominent players operating in the global chronic kidney disease market include Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, DaVita Inc., Nipro Corporation, Medtronic plc, and Amgen Inc.
These companies are focusing on strategic collaborations, research partnerships, and technological innovations to enhance their product portfolios and improve patient care outcomes. Continuous investments in new drug development, biologics, and dialysis system upgrades are likely to shape the competitive dynamics of the market.
Key Findings
- The chronic kidney disease market is set to reach USD 179.73 billion by 2035, growing at a CAGR of 4.41% from its 2024 valuation of USD 112.49 billion.
- The dialysis treatment segment continues to dominate, with hemodialysis maintaining its lead due to enhanced machine efficiency and widespread hospital adoption.
- North America accounted for the largest market share, which was around 45%, while Asia-Pacific is expected to exhibit the fastest growth rate during the forecast period, which translates into 20% of the market.
- Major industry participants such as Baxter International, Fresenius Medical Care, and DaVita are driving innovations through research, product development, and strategic partnerships.
